




**SINTX**  
Technologies

# **CORPORATE OVERVIEW**

March 2022

# WHO IS SINTX TECHNOLOGIES?

Salt Lake City – based advanced materials company that is focused on the manufacturing and development of advanced ceramic products.




# OUR VISION

We are dedicated to the manufacturing, research, and development of ceramic materials - specifically our silicon nitride.

We are committed to developing advanced material science – based solutions to improving the quality of human life and to expanding into multiple industries.

# SINTX HISTORY (From 1996 to Present)



# SINTX LEADERSHIP



**B. Sonny Bal, MD, JD, MBA, Ph.D**

CHAIRMAN OF THE BOARD CHIEF EXECUTIVE OFFICER

- Orthopedic surgeon and attorney
- Ceramic scientist and investigator
- CEO since 2014, board since 2012



**Ryan Bock, Ph.D.**

V.P. RESEARCH AND DEVELOPMENT

- 20 years research in advanced ceramics



**Donald Bray**

V.P. BUSINESS DEVELOPMENT – INDUSTRIAL & ARMOR

- 35 years background and experience in technical ceramics and business development



**David O'Brien**

CHIEF OPERATING OFFICER

- 30 years of operations, manufacturing, and engineering experience with medical devices and ceramics



**Joseph Palomo**

V.P. BUSINESS DEVELOPMENT - ANTIPATHOGENIC

- 40 years of product development and manufacturing experience in protective apparel and medical devices



**Michael Marcroft**

V.P. BUSINESS DEVELOPMENT - BIOMEDICAL

- 20 years of experience in medical technology business development & marketing

# OUR MANUFACTURING EXPERTISE

30,000 sq. ft.  
FDA registered,  
ANVISA registered,  
and ISO certified  
facility

R&D and product  
development  
laboratories

Vertically  
integrated for  
rapid prototyping  
and development

Rigorous quality  
control process

We are expanding a new 10,000 sq. ft. facility in Salt Lake City to manufacture body and vehicle armor products.

# STRONG R&D IS A CORE STRENGTH

## Our Innovations:

- Composites of silicon nitride and polymers
- Coatings of silicon nitride on other materials
- Enhanced formulations of silicon nitride
- Metal/silicon nitride composites
- Infiltration of fabrics and wound dressings with silicon nitride



# STRONG, ACTIVE IP PORTFOLIO

## Current focus is on patent applications for:

- Antibacterial and antipathogenic applications for silicon nitride
- Silicon nitride composites and coatings used in medical implants
- Silicon nitride manufacturing and formulation processes



14 Patents Issued

50 Patent Applications

SINTX sold numerous spine-specific patents and patent applications to CTL in 2018.



# SCIENTIFIC ACHIEVEMENTS

Over 130 peer-reviewed scientific publications/conference proceedings

More than 85 technical and scientific presentations

Most, if not all our findings have been corroborated by independent centers





Comprehensive *in vitro* comparison of cellular and osteogenic response to alternative biomaterials for spinal implants

Seunghun S. Lee <sup>a, R</sup>, Stephanie Huber, Stephen J. Ferguson <sup>a, R</sup>



Biological responses to silicon and nitrogen-rich PVD silicon nitride coatings

E. Marin <sup>a, b, R, R</sup>, F. Boschetto <sup>a, c</sup>, M. Zanocco <sup>a, c</sup>, W. Zhu <sup>a</sup>, T. Adachi <sup>b</sup>, N. Kanamura <sup>b</sup>, T. Yamamoto <sup>b</sup>, B.J. McEntire <sup>d</sup>, E.N. Jones <sup>d</sup>, C. Powell <sup>e</sup>, J. Hendry <sup>d</sup>, R.M. Bock <sup>d</sup>, B.S. Bai <sup>d</sup>, G. Pezzotti <sup>a, c, f</sup>



Full length article  
Antifungal activity of polymethyl methacrylate/Si<sub>3</sub>N<sub>4</sub> composites against *Candida albicans*

Giuseppe Pezzotti <sup>a, b, c, d, e, f, R, R</sup>, Tenma Asai <sup>a</sup>, Tetsuya Adachi <sup>a</sup>, Eriko Ohgihara <sup>d</sup>, Toshiro Yamamoto <sup>d</sup>, Narisato Kanamura <sup>e</sup>, Francesco Boschetto <sup>a, c</sup>, Wenliang Zhu <sup>a</sup>, Matteo Zanocco <sup>a, c</sup>, Elia Marin <sup>a, b</sup>, B. Sonny Bai <sup>d</sup>, Bryan J. McEntire <sup>d</sup>, Koichi Makimura <sup>e</sup>, Osam Mazda <sup>d</sup>, Ichiro Nishimura <sup>d, j</sup>

# TARGET MARKETS AS OF 2022



## BIOMEDICAL

- Used in over 40,000 human spine implantations
- Expanding with composites and coatings



## ANTIPATHOGENIC

- Antibacterial, antifungal, and antiviral applications
- Applications to PPE, filters, surfaces, coatings, wound care, catheters, wound drains, incontinence, and fem care



## INDUSTRIAL/ARMOR

- Able to withstand extreme conditions
- Used in aerospace, bearings, and drilling
- Personnel, aerospace, and vehicle protection



## EXAMPLES OF OUR MATERIALS PORTFOLIO

# SINTX SILICON NITRIDE (Solid, Nanostructured)

- Favorable to human cells and promotes bone fusion.
- Discourages bacterial adhesion on its surface.
- Inactivates bacteria, fungi, and viruses – including the SARS-CoV-2 virus.
- Versatile – amenable to development of composites and coatings
- NOTE – FDA approved for spine fusion implants, >40,000 implants



# ADVANTAGES OF SILICON NITRIDE IN BONE FUSION

## Faster Bone Healing

- Function of nanostructure and chemistry
- Enhances cell response for faster bone fusion

## Antipathogenic Properties

- Resistant to bacteria, viruses, and fungi

## Superior Radiographic Imaging


- Easy to see on x-ray, CT, and MRI
- No image distortion



ALL CLAIMS CONFIRMED INDEPENDENTLY


# POROUS AND LASER TEXTURED IMPLANTS

- Aimed at improving surface texture
- Pore size and laser texturing are ideal for bony in-growth
- First sales to spine partner in 2021
- Commercial discussions under way in foot & ankle market




# SN-PEEK COMPOSITE

- Extruded compound of silicon nitride and PEEK (poly[ether ether ketone])
- Can be machined into implants
- Combines familiarity and machinability of PEEK with silicon nitride
- Retains antibacterial and osteogenic properties
- Covered under US Patent 10,806,831
- FDA Master File submitted in early 2021
- First sales in 2021



# NON-WOVEN FABRIC INFILTRATED WITH SILICON NITRIDE

- Fabrics have demonstrated contact inactivation of multiple viral strains, including SARS-CoV-2
- Applications include masks, filters, wound care, etc.
- Developed additional antipathogenic grade of silicon nitride powder, with first sale in 2021



SN Embedded in Fabric



Wound Dressing (Under Development)



# SINTX ARMOR

## **BoroShock**

A 100% boron carbide material for ultimate lightweight performance in ballistic applications.

## **DuraShock**

A composite material made of boron carbide and silicon carbide (licensed from Precision Ceramics USA) for exceptional multi-hit performance against ballistic threats.



# 2022 KEY OBJECTIVES

## EXECUTE ON THE LAUNCH OF SINTX ARMOR

- Get the new facility fully operational in the 1<sup>st</sup> half of the year
- Generate revenue in the 3<sup>rd</sup> quarter

## DEVELOP NEW LINES OF REVENUE

- New markets: Antipathogenic & Industrial
- New non-spine products
- Pursue M&A opportunities

## EXPAND SILICON NITRIDE'S SUCCESSES IN SPINE

- New materials (SN-PEEK), new manufacturing technologies, new global markets

## CONTINUE ROBUST R&D PROGRAM

- Maintain leadership, monitor competitive landscape
- Co-develop new products with external partners



# 2022 CATALYSTS FOR GROWTH

# BIOMEDICAL CATALYSTS FOR GROWTH IN 2022

**Spine** – Awarded a \$300k NIH grant for 3D printed composite implants; collaboration with Drexel University and Thomas Jefferson University

**Foot and Ankle** – Leveraging success in the spine market to attract interest from this market in existing and new manufacturing technologies

**Arthroplasty** – Agreement with global medical device manufacturer to develop orthopedic implant coatings

**Wound Care** – Prototype development ongoing with two global wound care companies

**Craniomaxillofacial** – \$300K grant application to NIH for 3D printed composite implants; collaboration with Drexel University, Thomas Jefferson University, and University of Pennsylvania



# ANTIPATHOGENIC CATALYSTS FOR GROWTH IN 2022

Silicon nitride is proven to inactivate wide range of bacteria, fungi, and viruses, including SARS-CoV-2 (Claims verified independently)

## Partnership Agreements

- Iwatani Corporation: Filters and coatings
- (Confidential): Antipathogenic face masks and mask filters
- Several other partnership agreements in process



# INDUSTRIAL CATALYSTS FOR GROWTH IN 2022

**Armor** - Complete technology transfer, add necessary infrastructure to new Salt Lake City facility, and begin production.

**Aerospace** – Preferred material due to mechanical robustness and ability to perform at high temperatures

**Automotive** – Extends contact fatigue life through material strength, toughness, and resistance to chemical and thermal factors

**Energy** – Corrosion resistance of material can help extend the life of solid oxide fuel cells

**Cutting Tools** – Enables high cutting speeds and feeds





THANK YOU

# DISCLAIMER

## Forward-Looking Statements

This presentation contains forward-looking statements about SINTX Technologies, Inc. (the “Company”). These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to the Company’s financial results, products, product candidates, the expected timing of the regulatory approval of our product candidates, regulatory processes and objectives, potential benefits of the Company’s product candidates, intellectual property and related matters, all of which involve known and unknown risks and uncertainties. Actual results may differ materially from the forward-looking statements discussed in this presentation.

Accordingly, the Company cautions investors not to place undue reliance on the forward-looking statements contained in, or made in connection with, this presentation. The forward-looking statements contained in this presentation are further qualified by the detailed discussion of risks and uncertainties set forth in the Company’s Annual Report on form 10-K filed with the Securities and Exchange Commission (SEC) on March 22, 2021, and in the Company’s other filings with the SEC which can be obtained on the Company’s website at [www.sintx.com](http://www.sintx.com) or on the SEC website at [www.sec.gov](http://www.sec.gov). The forward-looking statements contained in this document represent the Company’s estimates and assumptions only as of the date of this presentation and the Company undertakes no duty or obligation to update or revise publicly any forward-looking statements contained in this presentation as a result of new information, future events or changes in the Company’s expectations.

\*\* Supporting documentation for all claims in this presentation can be found at <https://sintx.com/resources/references/>